Posted by Michael Wonder on 11 Nov 2022
Amneal announces US FDA filing acceptance of new drug application for IPX203 for the treatment of Parkinson’s disease
11 November 2022 - The FDA has assigned a PDUFA date of 30 June 2023.
Amneal Pharmaceuticals today announced the US FDA has accepted for review the new drug application for IPX203 for the treatment of Parkinson’s disease.
